Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Geron Corporation - Common Stock (NQ:GERN)

1.390 +0.120 (+9.45%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Geron Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Earnings Scheduled For February 26, 2025
Via Benzinga
Geron to Participate at Upcoming Investor Conferences in March 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
4 Analysts Assess Geron: What You Need To Know
Via Benzinga
Analyst Scoreboard: 4 Ratings For Geron
Via Benzinga
Analyst Ratings For Geron
Via Benzinga
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS
From Geron Corporation
Via Business Wire
Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies
From Geron Corporation
Via Business Wire
Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis
From Geron Corporation
Via Business Wire
Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
From Geron Corporation
Via Business Wire
Geron to Participate in the Stifel 2024 Healthcare Conference
From Geron Corporation
Via Business Wire
Geron (GERN) Q3 2024 Earnings Call Transcript
GERN earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million
From Royalty Pharma plc
Via GlobeNewswire
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
From Geron Corporation
Via Business Wire
Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Geron Corporation
Via Business Wire
Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
From Geron Corporation
Via Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
From Geron Corporation
Via Business Wire
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Geron Corporation
Via Business Wire
Geron (GERN) Q2 2024 Earnings Call Transcript
GERN earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024
GERN stock results show that Geron met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.